← Back to Search

68Ga-FAPI PET Scan for Cancer

Phase 2

Waitlist Available

Led By Carina A Mari, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

Study Summary

This trial is testing the use of a radioactive substance called 68Ga-FAPI as a possible cancer-detecting agent. The substance attaches to cancer-activated cells, and by using a PET scanner, doctors may be able to see smaller tumors than with standard imaging.

Eligible Conditions

Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Feasibility of 68Ga-FAPI PET

Trial Design

1Treatment groups

Experimental Treatment

Group I: 68Ga-FAPI PET/CTExperimental Treatment3 Interventions

Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Positron Emission Tomography (PET) scan

2016

Completed Phase 2

~190

68Ga-FAPI

2022

Completed Phase 2

~30

Computed Tomography (CT) scan

2017

Completed Phase 3

~180

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,387 Previous Clinical Trials

17,334,020 Total Patients Enrolled

Carina A Mari, MDPrincipal InvestigatorStanford Universiy

Media Library

68Ga-FAPI Clinical Trial Eligibility Overview. Trial Name: NCT04023240 — Phase 2

Cancer Research Study Groups: 68Ga-FAPI PET/CT

Cancer Clinical Trial 2023: 68Ga-FAPI Highlights & Side Effects. Trial Name: NCT04023240 — Phase 2

68Ga-FAPI 2023 Treatment Timeline for Medical Study. Trial Name: NCT04023240 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the age exclusion criterion for this clinical experiment include those aged 40 and above?

"As per the requirements of this clinical trial, participants must be aged between 19 and 99."

Answered by AI

To whom is participation in this research open?

"This clinical trial is currently seeking 30 participants aged 19 to 99 with malignancies. To be eligible, prospective patients must verify their diagnosis through imaging or pathology and provide written consent for the study. Additionally, individuals of reproductive age will need to undergo a pregnancy test prior to recruitment."

Answered by AI

Has the Food and Drug Administration given their seal of approval to 68Ga-FAPI?

"Following our assessment, the safety of 68Ga-FAPI was ranked 2 due to the absence of efficacy data from Phase 2 trials. However, there is some evidence demonstrating its security."

Answered by AI

Are there still vacancies available for this experiment?

"According to clinicaltrials.gov, this research project is no longer actively recruiting patients; it was first published on January 1st 2023 and last edited November 9th 2022. However, there are a plethora of other trials currently in need of participants at present - 2795 to be exact!"

Answered by AI

Recent research and studies

clinicaltrials.govStudy

68-Ga-FAPI PET Imaging in Malignancy

2023. "68-Ga-FAPI PET Imaging in Malignancy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04023240.